Comparative study of a new dermal filler Uma Jeunesse ® and Juvéderm ®

Summary Introduction  Innovation in technology has resulted in the emergence of better, longer‐lasting hyaluronic acid implants with fewer side effects. The new dermal implant Uma Jeunesse ® was compared to Juvéderm ® in this split‐face study. Methods  Uma Jeunesse ® is crosslinked with butanediol diglycidyl ether (BDDE) using a new crosslinking technology. Uma Jeunesse ® and Juvéderm ® Ultra 3 were injected in a split‐face study on 17 healthy volunteers, whose ages ranged from 33–58 years. There were 14 women and three men with medium to deep nasolabial folds. All subjects randomly received either Uma Jeunesse ® or Juvéderm ® Ultra 3 on one half of their face. Patients were followed up for 9 months. Results  Juvéderm ® was easier to inject with lesser injection pain because of lidocaine, but late postinjection pain was much less with Uma Jeunesse ® as compared to Juvéderm ® . Overall rate of early and late complications as well as adverse events was lower with Uma Jeunesse ® than Juvéderm ® . After 9 months of follow‐up, Uma Jeunesse ® lasted in tissues for longer as compared to Juvéderm ® even in patients injected for the first time ( P  <   0.0001). Patient acceptability rate of Uma Jeunesse ® was also much higher. Perception of pain during injection was lesser with Juvéderm ® probably because of the presence of lidocaine. Conclusion  The new dermal implant Uma Jeunesse ® is a safe and patient‐friendly product which resides in the tissues for longer with maintenance of aesthetic effect over and beyond 6 months, reaching 9 months in over 80% of patients, and Juvéderm ® injection is less painful.